Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

One Day, a picture book by the beloved children’s author, follows the true story of a father and son escaping Auschwitz by train ...

Simultaneous discoveries in art and science highlight humanity's shared creativity, problem-solving, and the ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company focused on ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

Here’s what you can do to help boost your brain’s neurogenesis.

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the stock market. The post 2 bold stock market ideas to consider for a Stocks and ...

Crispr Therapeutics and its partner Vertex Pharmaceuticals ... Archer’s currently well-capitalised and its order book now exceeds $6bn. Finally, Morgan Stanley estimates the eVTOL market could ...

In the literary world, this year is shaping up to be a good one for fans of cultural criticism: There are new books about Better Call Saul and biographies of James Gandolfini and Lorne Michaels on ...